How Gilead Lost $7.8B in October Alone Post author:Sam Post published:November 2, 2017 Post category:BioPharma Gilead Sciences’ third-quarter financial results were dismal, to say the least. Source: BioSpace You Might Also Like Why M&A Hungry Sanofi Could be Gearing Up to Buy Sarepta April 30, 2017 Sweden's Active Biotech is Strapped for Cash and May Not Survive 2018 December 7, 2017 Jacobson Pharma Announces 2017 Annual Results June 26, 2017
